DUBLIN–(Business Wire)–
Research and Markets
(http://www.researchandmarkets.com/research/22745f/looking_at_offshor) has
announced the addition of the “Looking at Offshoring in the Pharmaceutical
Industry” report to their offering.

The organic spread of pharmaceutical industry worldwide has necessitated taking
steps beyond only export of drug lifecycles across time based zones to
development in those countries itself in order to capitalize on the
opportunities present in these countries whether in terms of knowledge resources
or as financial capabilities. These opportunities exist in terms of
manufacturing APIs or intermediate and final stage drugs. Offshoring is helping
these companies develop application specific drugs, share knowledge and transmit
the benefits of such research across the globe irrespective of borders.

Manufacturers are turning to labor intensive emerging markets like India and
China for fulfilling these additional capacity requirements. Such offshoring of
R&D as well as production efforts are guided by pressures of rising costs,
market competition, regulatory allowances, intense generic proliferation or
deriving better efficiencies. The route to entering such markets by these global
majors are being explored in India and China by acquiring local companies or
setting up wholly owned R& D subsidiaries.

While Pharma revenue growth in the seven major pharmaceutical markets has begun
to slow, with five percent annual growth in 2004-2005, growth in the BRIC
(Brazil, Russia, India and China) markets was significantly higher at 22%.
Consequently, in addition to acting as key sights for off-shoring drug
development and manufacturing, India and China are increasingly becoming key
targets for Western companies aiming to expand their global pharmaceutical
revenues.

Aruvian’s R’searchs report – Looking at Offshoring in the Pharmaceutical
Industry – is a detailed analysis of the recent practice of offshoring which has
been initiated in the pharmaceutical industry globally and the reasons behind
the need for and benefits derived from offshoring by these companies.

The report presents a demarcation of the industry and profiles the industry in
various marketing dimensions as the segments active in the industry; the
competitive forces at play and an outlook for the market. The report explains
the basic concepts of Offshoring as implemented in the pharmaceutical sector by
analyzing the value chains which have materialized globally pushing employment
scenarios in emerging and growing economies.

The impact of Offshoring as a practice cannot be understood without a complete
study of Indian and Chinese knowledge markets to the global pharma chains as
explained in this report along with the challenges or barriers faced by inflow
of offshoring pharma investment by R&D routes into these markets.

The report also provides an in depth explanation of the pharma manufacturing
process as is prevalent in the leading markets wherein pharma companies are
straddled with decisions to manufacture biologics or secondaries in offshoring
bases and the challenges expected in these markets towards such initiatives.

The report is a complete guide on Offshoring as being implemented in the current
scenario for the pharmaceutical industry and the future outlook for growth of
off shoring opportunities which can lead to mutually acceptable gains for the
investors and the suppliers in the pharma industry.

Aruvian Research’s report – Looking at Offshoring in the Pharmaceutical Industry
- is a detailed analysis of the recent practice of offshoring which has been
initiated in the pharmaceutical industry globally and the reasons behind the
need for and benefits derived from offshoring by these companies.

The report presents a demarcation of the industry and profiles the industry in
various marketing dimensions as the segments active in the industry; the
competitive forces at play and an outlook for the market. The report explains
the basic concepts of Offshoring as implemented in the pharmaceutical sector by
analyzing the value chains which have materialized globally pushing employment
scenarios in emerging and growing economies.

The impact of Offshoring as a practice cannot be understood without a complete
study of Indian and Chinese knowledge markets to the global pharma chains as
explained in this report along with the challenges or barriers faced by inflow
of offshoring pharma investment by R&D routes into these markets.

The report also provides an in depth explanation of the pharma manufacturing
process as is prevalent in the leading markets wherein pharma companies are
straddled with decisions to manufacture biologics or secondaries in offshoring
bases and the challenges expected in these markets towards such initiatives.

The report is a complete guide on Offshoring as being implemented in the current
scenario for the pharmaceutical industry and the future outlook for growth of
off shoring opportunities which can lead to mutually acceptable gains for the
investors and the suppliers in the pharma industry.

Key Topics Covered:

* Executive Summary
* Introduction to the Global Pharmaceutical Industry
* Offshoring in the Pharmaceutical Sector
* Offshoring of R&D
* Offshoring of Pharmaceutical Manufacturing Processes
* Appendix
* Glossary of Terms

For more information visit

http://www.researchandmarkets.com/research/22745f/looking_at_offshor

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2010